Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
Data from Phase 2 Clinical Trial May Also Provide Insights into Diabetes- and Obesity-related Complications MONTREAL–(BUSINESS WIRE)– Inversago Pharma Inc. (“Inversago”), a clinical stage biotech...